Cerus Co. (NASDAQ:CERS) has earned a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.50.
A number of equities analysts recently issued reports on the company. BTIG Research reissued a “hold” rating on shares of Cerus in a report on Thursday, January 25th. Zacks Investment Research lowered Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus in a report on Tuesday, January 23rd. Robert W. Baird reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus in a report on Friday, December 1st. Finally, BidaskClub raised Cerus from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th.
Shares of Cerus (CERS) traded down $0.08 during mid-day trading on Tuesday, reaching $3.85. The company had a trading volume of 744,600 shares, compared to its average volume of 1,906,219. Cerus has a 1-year low of $1.93 and a 1-year high of $5.43. The company has a market cap of $488.95, a price-to-earnings ratio of -6.53 and a beta of 2.22. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.